 |
Market Cap | 144.41M | EPS (ttm) | -0.01 |
P/E | - | EPS this Y | -321.30% |
Forward P/E | - | EPS next Y | 64.85% |
PEG | - | EPS past 5Y | - |
P/S | 0.28 | EPS next 5Y | - |
P/B | 0.47 | EPS Q/Q | -189.47% |
Dividend | - | Sales Q/Q | -50.01% |
Insider Own | 13.28% | Inst Own | 51.13% |
Insider Trans | -0.30% | Inst Trans | -0.26% |
Short Float | 7.57% | Earnings | May 08/a |
Analyst Recom | 1.86 | Target Price | 3.05 |
Avg Volume | 1.05M | 52W Range | 1.39 - 5.68 |
|
|
May-09-25 | Downgrade |
BTIG Research |
Buy → Neutral |
|
|
|
DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services, Mobile Health Solutions, and Corporate. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The Corporate segment consists of information technology expenses. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Etalvina Leite | Officer | Dec 17 '24 | Proposed Sale | 4.33 | 16,500 | 71,528 | | Dec 17 05:30 PM | Leite Etalvina | Director | Dec 17 '24 | Sale | 4.34 | 16,500 | 71,610 | 51,411 | Dec 17 04:15 PM | Tendler Ely D | General Counsel and Secretary | Dec 16 '24 | Sale | 4.44 | 23,088 | 102,511 | 175,645 | Dec 16 05:22 PM | Elyahu Tendler | Officer | Dec 16 '24 | Proposed Sale | 4.49 | 23,088 | 103,665 | | Dec 16 05:09 PM | Burdiek Michael J | Director | May 14 '24 | Buy | 3.40 | 10,000 | 34,000 | 581,595 | May 14 04:10 PM |
|
|
 |
 |
Market Cap | 35.76M | EPS (ttm) | -1.64 |
P/E | - | EPS this Y | 22.33% |
Forward P/E | - | EPS next Y | 97.03% |
PEG | - | EPS past 5Y | 41.43% |
P/S | 1.35 | EPS next 5Y | - |
P/B | 8.19 | EPS Q/Q | 12.21% |
Dividend | - | Sales Q/Q | 23.44% |
Insider Own | 19.63% | Inst Own | 16.62% |
Insider Trans | 0.48% | Inst Trans | -14.07% |
Short Float | 5.06% | Earnings | May 07/a |
Analyst Recom | 1.00 | Target Price | 21.10 |
Avg Volume | 165.04K | 52W Range | 4.63 - 19.49 |
|
|
|
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Theofilos Charles Steve | Director | Mar 25 '25 | Proposed Sale | 7.39 | 65,000 | 480,675 | | Mar 25 10:26 AM | Goldberger Daniel S | Chief Executive Officer | Mar 17 '25 | Buy | 8.59 | 1,000 | 8,590 | 290,565 | Mar 18 10:52 AM | Errico Thomas J. | Director | Mar 17 '25 | Buy | 8.10 | 6,000 | 48,585 | 256,401 | Mar 17 08:00 PM | Errico Thomas J. | Director | Aug 15 '24 | Buy | 6.12 | 5,000 | 30,595 | 233,818 | Aug 19 09:37 AM | GANDOLFO JOHN P | Director | Jun 13 '24 | Buy | 6.43 | 1,000 | 6,430 | 50,704 | Jun 17 04:05 PM |
|
|
 |
 |
Market Cap | 0.82M | EPS (ttm) | -17.42 |
P/E | - | EPS this Y | 59.49% |
Forward P/E | - | EPS next Y | 75.05% |
PEG | - | EPS past 5Y | 83.98% |
P/S | - | EPS next 5Y | - |
P/B | 2.77 | EPS Q/Q | 87.43% |
Dividend | - | Sales Q/Q | -100.00% |
Insider Own | - | Inst Own | 1.34% |
Insider Trans | - | Inst Trans | 0.09% |
Short Float | - | Earnings | Apr 11/b |
Analyst Recom | 1.00 | Target Price | 18.00 |
Avg Volume | 1.88M | 52W Range | 1.14 - 74.00 |
|
|
|
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom. |
|
|  |
 |
Market Cap | 15.62M | EPS (ttm) | -1.00 |
P/E | - | EPS this Y | -120229.87% |
Forward P/E | - | EPS next Y | 21.62% |
PEG | - | EPS past 5Y | 82.03% |
P/S | 4.26 | EPS next 5Y | - |
P/B | 0.81 | EPS Q/Q | -152.75% |
Dividend | - | Sales Q/Q | -98.77% |
Insider Own | 2.91% | Inst Own | 9.19% |
Insider Trans | 0.00% | Inst Trans | -10.60% |
Short Float | 1.36% | Earnings | May 08/b |
Analyst Recom | 1.00 | Target Price | 6.75 |
Avg Volume | 12.95K | 52W Range | 2.75 - 11.79 |
|
|
|
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT. |
|
 |
 |
Market Cap | 782.22M | EPS (ttm) | 0.74 |
P/E | 34.74 | EPS this Y | 4.51% |
Forward P/E | 18.35 | EPS next Y | 29.62% |
PEG | 1.45 | EPS past 5Y | - |
P/S | 3.51 | EPS next 5Y | 23.98% |
P/B | 14.78 | EPS Q/Q | -71.35% |
Dividend | - | Sales Q/Q | 11.46% |
Insider Own | 55.30% | Inst Own | 37.16% |
Insider Trans | 0.00% | Inst Trans | 11.93% |
Short Float | 0.99% | Earnings | May 09/b |
Analyst Recom | 1.60 | Target Price | 38.78 |
Avg Volume | 106.98K | 52W Range | 26.00 - 53.86 |
|
|
Today | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
$32 |
|
|
Docebo, Inc. develops a cloud-based learning management platform. The firm's cloud platform consists of the following interrelated modules: Docebo Learn, Docebo Discover, Coach and Share, Docebo Extended Enterprise, Docebo Virtual Coach, Docebo Mobile Pages, Docebo Discover and Docebo Learning Impact. It also offers Docebo for Saleforce, Docebo Embed and Docebo Mobile App Publisher. The company was founded by Claudio Erba in 2005 and is headquartered in Toronto, Canada. |
|
|  |
 |
Market Cap | 2.13M | EPS (ttm) | -452.26 |
P/E | - | EPS this Y | 81.87% |
Forward P/E | - | EPS next Y | 8.52% |
PEG | - | EPS past 5Y | 80.96% |
P/S | - | EPS next 5Y | 51.40% |
P/B | 0.10 | EPS Q/Q | 99.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | 3.61% | Inst Own | 10.80% |
Insider Trans | 0.00% | Inst Trans | 1.24% |
Short Float | 7.50% | Earnings | Feb 14/b |
Analyst Recom | 1.00 | Target Price | 21.00 |
Avg Volume | 2.96M | 52W Range | 0.34 - 35.70 |
|
|
|
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA. |
|
 |
 |
Market Cap | 9.46M | EPS (ttm) | -0.43 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.43 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -155.08% |
Dividend | - | Sales Q/Q | - |
Insider Own | 57.14% | Inst Own | 0.75% |
Insider Trans | 0.00% | Inst Trans | 7.51% |
Short Float | 3.46% | Earnings | Feb 26 |
Analyst Recom | 1.00 | Target Price | 1.75 |
Avg Volume | 2.22M | 52W Range | 0.22 - 1.52 |
|
|
|
TruGolf Holdings, Inc. engages in the provision of indoor golf solutions. It offers video games, hardware solutions, and an e-sports platform. The company was founded by Christopher Jones in 1983 and is headquartered in Centerville, UT. |
|
|  |
 |
Market Cap | 7.66B | EPS (ttm) | 2.36 |
P/E | 8.46 | EPS this Y | -0.19% |
Forward P/E | 9.05 | EPS next Y | 7.17% |
PEG | 1.97 | EPS past 5Y | 4.36% |
P/S | 0.60 | EPS next 5Y | 4.30% |
P/B | 1.00 | EPS Q/Q | -4.92% |
Dividend | 6.27% | Sales Q/Q | -8.87% |
Insider Own | 0.00% | Inst Own | 6.58% |
Insider Trans | - | Inst Trans | -0.46% |
Short Float | 0.28% | Earnings | May 12/b |
Analyst Recom | 1.62 | Target Price | 23.30 |
Avg Volume | 391.36K | 52W Range | 20.28 - 24.58 |
|
|
Today | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
|
SK Telecom Co., Ltd. engages in the provision of telecommunication and internet services. It operates through the following business divisions: Wireless Communication, Wired Communication, and Other. The Wireless Communication division deals with mobile phone, wireless data, information, and communication business. The Wired Communication division provides phone, high-speed Internet, data, and communication network rental services. The Other division includes product sales-type data broadcasting channel use business. The company was founded on March 29, 1984 and is headquartered in Seoul, South Korea. |
|
 |
 |
Market Cap | 35.43M | EPS (ttm) | -453.51 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -50.01% |
P/S | 0.88 | EPS next 5Y | - |
P/B | 0.05 | EPS Q/Q | -319.69% |
Dividend | - | Sales Q/Q | - |
Insider Own | 0.49% | Inst Own | 0.46% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 13.60% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 961.57K | 52W Range | 7.41 - 3120.00 |
|
|
|
MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY. |
|
 |
 |
Market Cap | 19.16M | EPS (ttm) | -1.07 |
P/E | - | EPS this Y | 35.98% |
Forward P/E | - | EPS next Y | -13.38% |
PEG | - | EPS past 5Y | -1.48% |
P/S | - | EPS next 5Y | 50.47% |
P/B | 0.31 | EPS Q/Q | 32.79% |
Dividend | - | Sales Q/Q | - |
Insider Own | 15.33% | Inst Own | 44.67% |
Insider Trans | -3.23% | Inst Trans | 2.65% |
Short Float | 3.42% | Earnings | Mar 04/b |
Analyst Recom | 1.00 | Target Price | 7.67 |
Avg Volume | 174.34K | 52W Range | 0.30 - 1.55 |
|
|
|
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ORBIMED ADVISORS LLC | 10% Owner | Apr 23 '25 | Sale | 0.34 | 89,328 | 30,372 | 6,718,195 | Apr 24 05:38 PM | ORBIMED ADVISORS LLC | 10% Owner | Apr 22 '25 | Sale | 0.34 | 78,049 | 26,537 | 6,807,523 | Apr 24 05:38 PM | ORBIMED ADVISORS LLC | 10% Owner | Apr 24 '25 | Sale | 0.32 | 68,195 | 21,822 | 6,650,000 | Apr 24 05:38 PM | ORBIMED ADVISORS LLC | 10% Owner | Apr 17 '25 | Sale | 0.33 | 77,090 | 25,440 | 6,885,572 | Apr 17 06:10 PM | ORBIMED ADVISORS LLC | 10% Owner | Apr 16 '25 | Sale | 0.33 | 61,638 | 20,341 | 6,962,662 | Apr 17 06:10 PM |
|
|
|